Production (Stage)
Lotus Pharmaceuticals, Inc.
LTUS
$0.005
-$0.0009-15.25%
OTC PK
| 09/30/2011 | 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | |
|---|---|---|---|---|---|
| Revenue | 70.79M | 70.05M | 70.27M | 72.10M | 68.48M |
| Total Other Revenue | -- | -- | 198.50K | 396.90K | 595.50K |
| Total Revenue | 70.79M | 70.05M | 70.27M | 72.10M | 68.48M |
| Cost of Revenue | 45.94M | 38.14M | 33.44M | 32.92M | 31.40M |
| Gross Profit | 24.85M | 31.92M | 36.83M | 39.18M | 37.07M |
| SG&A Expenses | 15.33M | 17.35M | 18.39M | 18.41M | 14.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.23M | 56.99M | 52.64M | 51.41M | 45.87M |
| Operating Income | 7.57M | 13.06M | 17.62M | 20.69M | 22.60M |
| Income Before Tax | 1.49M | 7.13M | 11.85M | 14.65M | 21.32M |
| Income Tax Expenses | -250.10K | -49.80K | 118.20K | 220.30K | 682.30K |
| Earnings from Continuing Operations | 1.74 | 7.18 | 11.73 | 14.42 | 20.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.74M | 7.18M | 11.73M | 14.42M | 20.64M |
| EBIT | 7.57M | 13.06M | 17.62M | 20.69M | 22.60M |
| EBITDA | 9.71M | 15.24M | 19.83M | 22.94M | 24.84M |
| EPS Basic | 0.06 | 0.26 | 0.44 | 0.56 | 0.80 |
| Normalized Basic EPS | 0.19 | 0.32 | 0.44 | 0.51 | 0.57 |
| EPS Diluted | 0.06 | 0.26 | 0.43 | 0.53 | 0.77 |
| Normalized Diluted EPS | 0.19 | 0.32 | 0.43 | 0.50 | 0.54 |
| Average Basic Shares Outstanding | 109.73M | 108.64M | 107.40M | 104.69M | 101.11M |
| Average Diluted Shares Outstanding | 110.66M | 109.62M | 108.49M | 107.55M | 107.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |